Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21Cip1

Molecular Cell

Volumn 11, Issue 6, 2003, Pages 1491-1501

  Huang, Shile ^a   Shu, Lili ^a   Dilling, Michael B ^a   Easton, John ^a   Harwood, Franklin C ^a   Ichijo, Hidenori ^b   Houghton, Peter J ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; BINDING PROTEIN; INITIATION FACTOR 4E BINDING PROTEIN 1; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOTRANSFERASE; PROTEIN C JUN; PROTEIN P53; RAPAMYCIN; SIGNAL REGULATING KINASE 1; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL VIABILITY; CONTROLLED STUDY; DRUG ACTIVITY; HUMAN; HUMAN CELL; INHIBITION KINETICS; NUCLEOTIDE SEQUENCE; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

EUKARYOTA; MAMMALIA;

EID: 0038094504     PISSN: 10972765     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1097-2765(03)00180-1     Document Type: Article

References (42)

1. Cip1/WAF1 in monocytic differentiation. EMBO J. 18:1999;1223-1234.
2. 2-terminal protein kinase-related cell death pathway. Mol. Pharmacol. 60:2001;847-856.
3. Brown P.H., Chen T.K., Birrer M.J. Mechanism of action of a dominant-negative mutant of c-Jun. Oncogene. 9:1994;791-799.
4. Brunn G.J., Hudson C.C., Sekulic A., Williams J.M., Hosoi H., Houghton P.J., Lawrence J.C., Abraham R.T. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science. 277:1997;99-104.
5. Chang L., Karin M. Mammalian MAP kinase signalling cascades. Nature. 410:2001;37-40.
6. Chuang S.M., Wang I.C., Yang J.L. Roles of JNK, p38 and ERK mitogen-activated protein kinases in the growth inhibition and apoptosis induced by cadmium. Carcinogenesis. 21:2000;1423-1432.
7. Chung J., Kuo C.J., Crabtree G.R., Blenis J. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell. 69:1992;1227-1236.
8. Cui W., Yazlovitskaya E.M., Mayo M.S., Pelling J.C., Persons D.L. Cisplatin-induced response of c-jun N-terminal kinase 1 and extracellular signal-regulated protein kinases 1 and 2 in a series of cisplatin-resistant ovarian carcinoma cell lines. Mol. Carcinog. 29:2000;219-228.
9. Davis R.J. Signal transduction by the JNK group of MAP kinases. Cell. 103:2000;239-252.
10. s6k phosphorylation sites, T-229 and T-389, are differentially regulated by rapamycin-insensitive kinase kinases. Mol. Cell. Biol. 16:1996;6242-6251.
11. Dennis P.B., Jaeschke A., Saitoh M., Fowler B., Kozma S.C., Thomas G. Mammalian TOR. a homeostatic ATP sensor Science. 294:2001;1102-1105.
12. Deschesnes R.G., Huot J., Valerie K., Landry J. Involvement of p38 in apoptosis-associated membrane blebbing and nuclear condensation. Mol. Biol. Cell. 12:2001;1569-1582.
13. Di Como C.J., Arndt K.T. Nutrients, via the Tor proteins, stimulate the association of Tap42 with type 2A phosphatases. Genes Dev. 10:1996;1904-1916.
14. Dilling M.B., Dias P., Shapiro D.N., Germain G.S., Johnson R.K., Houghton P.J. Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor. Cancer Res. 54:1994;903-907.
15. Dilling M.B., Germain G.S., Dudkin L., Jayaraman A.L., Zhang X., Harwood F.C., Houghton P.J. 4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin. J. Biol. Chem. 277:2002;13907-13917.
16. Gingras A.C., Raught B., Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev. 15:2001;807-826.
17. Hardwick J.S., Kuruvilla K.G., Tong J.K., Shamli A.F., Schreiber S.L. Rapamycin-modulated transcription defines the subset of nutrient-sensitive signaling pathways directly controlled by the Tor proteins. Proc. Natl. Acad. Sci. USA. 96:1999;14866-14871.
18. Hosoi H., Dilling M.B., Liu L.N., Danks M.K., Shikata T., Sekulic A., Abraham R.T., Lawrence J.C. Jr., Houghton P.J. Studies on the mechanism of resistance to rapamycin in human cancer cells. Mol. Pharmacol. 54:1998;815-824.
19. Hosoi H., Dilling M.B., Shikata T., Liu L.N., Shu L., Ashmun R.A., Germain G.S., Abraham R.T., Houghton P.J. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res. 59:1999;886-894.
20. 1 arrest and determine the cellular response to rapamycin. Cancer Res. 61:2001;3373-3381.
21. Ichijo H., Nishida E., Irie K., ten Dijke P., Saitoh M., Moriguchi T., Takagi M., Matsumoto K., Miyazono K., Gotoh Y. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science. 275:1997;90-94.
22. Kim D.H., Sarbassov D.D., Ali S.M., King J.E., Latek R.R., Erdjument-Bromage H., Tempst P., Sabatini D.M. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell. 110:2002;163-175.
23. Kuo C.J., Chung J., Fiorentino D.F., Flanagan W.M., Blenis J., Crabtree G.R. Rapamycin selectively inhibits interleukin-2 activation of p70S6K. Nature. 358:1992;70-73.
24. Lee F.S., Hagler J., Chen Z.J., Maniatis T. Activation of the IkappaB alpha kinase complex by MEKK1, a kinase of the JNK pathway. Cell. 88:1997;213-222.
25. Lin T.-A., Kong X., Haystead T.A.J., Pause A.S., Belsham G., Sonenberg N., Lawrence J.C. Jr. PHAS-I as a link between mitogen-activated protein kinase and translation initiation. Science. 266:1994;653-656.
26. Louro I.D., McKie-Bell P., Gosnell H., Brindley B.C., Bucy R.P., Ruppert J.M. The zinc finger protein GLI induces cellular sensitivity to the mTOR inhibitor rapamycin. Cell Growth Differ. 10:1999;503-516.
27. Morita K., Saitoh M., Tobiume K., Matsuura H., Enomoto S., Nishitoh H., Ichijo H. Negative feedback regulation of ASK1 by protein phosphatase 5 (PP5) in response to oxidative stress. EMBO J. 20:2001;6028-6036.
28. Neshat M.S., Mellinghoff I.K., Tran C., Stiles B., Thomas G., Petersen R., Frost P., Gibbons J.J., Wu H., Sawyers C.L. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. USA. 98:2001;10314-10319.
29. Osborn M.T., Chambers T.C. Role of the stress-activated/c-Jun NH2-terminal protein kinase pathway in the cellular response to adriamycin and other chemotherapeutic drugs. J. Biol. Chem. 271:1996;30950-30955.
30. Paddison P.J., Caudy A.A., Bernstein E., Hannon G.J., Conklin D.S. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev. 16:2002;948-958.
31. Peng T., Golub T.R., Sabatini D.M. The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation. Mol. Cell. Biol. 22:2002;5575-5584.
32. Peterson R.T., Desai B.N., Hardwick J.S., Schreiber S.L. Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycin associated protein. Proc. Natl. Acad. Sci. USA. 96:1999;4438-4442.
33. Proud C.G. Regulation of mammalian translation factors by nutrients. Eur. J. Biochem. 269:2002;5338-5349.
34. Shaulian E., Schreiber M., Piu F., Beeche M., Wagner E.F., Karin M. The mammalian UV response. c-Jun induction is required for exit from p53-imposed growth arrest Cell. 103:2000;897-907.
35. Shim J., Lee H., Park J., Kim H., Choi E.J. A non-enzymatic p21 protein inhibitor of stress-activated protein kinases. Nature. 381:1996;804-806.
36. Stone A.A., Chambers T.C. Microtubule inhibitors elicit differential effects on MAP kinase (JNK, ERK, and p38) signaling pathways in human KB-3 carcinoma cells. Exp. Cell Res. 254:2000;110-119.
37. Tee A.R., Fingar D.C., Manning B.D., Kwiatkowski D.J., Cantley L.C., Blenis J. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci USA. 99:2002;13571-13576.
38. Tobiume K., Matsuzawa A., Takahashi T., Nishitoh H., Morita K., Takeda K., Minowa O., Miyazono K., Noda T., Ichijo H. ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis. EMBO Rep. 2:2001;222-228.
39. Tournier C., Hess P., Yang D.D., Xu J., Turner T.K., Nimnual A., Bar-Sagi D., Jones S.N., Flavell R.A., Davis R.J. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science. 288:2000;870-874.
40. Whitfield J., Neame S.J., Paquet L., Bernard O., Ham J. Dominant-negative c-Jun promotes neuronal survival by reducing BIM expression and inhibiting mitochondrial cytochrome c release. Neuron. 29:2001;629-643.
41. Zhang X., Shu L., Hosoi H., Murti K.G., Houghton P.J. Predominant nuclear localization of mammalian target of rapamycin in normal and malignant cells in culture. J. Biol. Chem. 277:2002;28127-28134.
42. Zhu W., Zou Y., Aikawa R., Harada K., Kudoh S., Uozumi H., Hayashi D., Gu Y., Yamazaki T., Nagai R.et al. MAPK superfamily plays an important role in daunomycin-induced apoptosis of cardiac myocytes. Circulation. 100:1999;2100-2107.